Navidea Biopharmaceuticals, Inc.

Company Information
Address 4995 Bradenton Ave Ste 240
Dublin, OH, 43017-3552

http://www.navidea.com

Information

DUNS: 131891467

# of Employees: 57


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages

    Amount: $939,552.00

    Summary Abstract Kaposi sarcoma KS is a potentially life threatening consequence of immunosuppression in patients that are infected with human herpes virus HHV Most KS occurs in patients wit ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages

    Amount: $232,464.00

    DESCRIPTION provided by applicant Kaposi sarcoma KS is a potentially life threatening consequence of immunosuppression in patients that are infected with human herpes virus HHV Most KS occ ...

    SBIRPhase I2016Department of Health and Human Services
  3. 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages

    Amount: $1,500,000.00

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking SBIR Fast Track grant support for preclinical animal studies and a regulatory phase clinical study of the ability of m ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  4. Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept

    Amount: $1,500,000.00

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals has developed mTc tilmanocept as a radiopharmaceutical diagnostic imaging agent targeted to the macrophage mannose receptor CD to ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  5. 99mTc-Tilmanocept Targeting of Cardiovascular Plaque in HIV Subjects

    Amount: $321,838.00

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking support to progress efforts designed ultimately to determine if its diagnostic imaging agent mTc tilmanocept can be used ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  6. CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv

    Amount: $1,226,270.00

    DESCRIPTION provided by applicant After an interim period of inactivity based on a select alternative commercial focus and after consultation with the FDA Neoprobe Corporation is rapidly reinitia ...

    SBIRPhase II2015Department of Health and Human Services
  7. 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages

    Amount: $224,993.00

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals is seeking SBIR Fast Track grant support for preclinical animal studies and a regulatory phase clinical study of the ability of m ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  8. 99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries

    Amount: $1,500,000.00

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals Navidea is seeking SBIR FastTrack grant support to investigate the clinical utility safety and efficacy of its new product mTc ti ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  9. Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept

    Amount: $300,000.00

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals has developed mTc tilmanocept as a radiopharmaceutical diagnostic imaging agent targeted to the macrophage mannose receptor CD to ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  10. 99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries

    Amount: $165,917.00

    DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals (Navidea) is seeking SBIR FastTrack grant support to investigate the clinical utility, safety, and efficacy of its new product, 99mTc-ti ...

    SBIRPhase I2014Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government